LUND, Sweden, May 16, 2022 /PRNewswire/ — Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Nathalie Carfora as the Market Access Manager of its US subsidiary, Immunovia, Inc. Natalie brings deep expertise to the reimbursement process through her previous Market Access roles at Scipher Medicine and Myriad Genetics. Natalie will take office on May 23, 2022.
“The hiring of Natalie as Market Access Manager in the US is another key hire in line with our strategic priority to strengthen our US team for commercial scale-up of IMMray™ PanCan- d in the U.S. Natalie will be instrumental in the continued reimbursement coverage for IMMray™ PanCan-d in the U.S., the world’s largest and most attractive diagnostic market in which Immunovia markets its new test since August of last year,” says Philippe MatthewActing CEO and President, Immunovia AB.
“Establishing reimbursement for IMMray™ PanCan-d, the only blood test available for the early detection of pancreatic cancer, is important to achieve widespread use. Nathalie Carfora has a proven track record of obtaining reimbursement for new tests in a start-up environment at Scipher Medicine and at Myriad Genetics, one of the leading diagnostic companies in the United States. Adding his talents to the team is another important step in the adoption and growth of IMMray™ PanCan-d,” says Jeff BorcherdingCEO of Immunovia, Inc, the US subsidiary of Immunovia AB.
“Without precision medicine tools, patients suffer from late-stage diagnosis and a poor prognosis. People at risk for pancreatic cancer need much better ways to detect cancer earlier. The IMMray test ™ PanCan-d is a compelling clinical option for patients, providers and I am delighted to partner with payers to offer IMMray™ PanCan-d access to their members, which will result in better clinical outcomes, a increased patient satisfaction and cost-of-care savings,” says Nathalie Carfora.
Nathalie Carfora brings to the team over ten years of sales and market access experience in the biotechnology, medical device and pharmaceutical industries. Building partnerships across a variety of models across multiple channels, including payers, pharmacy benefit managers, and specialty pharmacies, she focuses on optimizing patient care management. Natalie graduated from Boston University School of Management with a BS in Business Administration.
For more information please contact:
CEO and Acting President
E-mail: [email protected]
Senior Director of Investor Relations and Corporate Communications
E-mail: [email protected]
Tel: +46 736 36 35 74
The information was submitted for publication on May 16, 2022to 08:30 CET.
Immunovia AB is a diagnostics company whose vision is to revolutionize blood diagnostics and increase survival rates for cancer patients.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unparalleled clinical performance. Commercialization of IMMray™ PanCan-d began in August 2021 in the UNITED STATES and IMMray™ PanCan-d is offered as a laboratory-developed test (LDT) exclusively by Immunovia, Inc. For more information, visit: www.immunovianc.com.
Immunovia is collaborating and engaging with healthcare providers, leading experts and patient advocacy groups around the world to make this test available to all high-risk pancreatic cancer groups.
the UNITED STATESthe first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than $4 billion annually.
Immunovia (IMMNOV) shares are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Immunovia AB